← Oncology Approval Tracker

FDA DECISION ·

Imjudo + Imfinzi

tremelimumab-actl plus durvalumab · AstraZeneca

FDA approvalNew therapyHepatocellular carcinoma
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Adults with unresectable hepatocellular carcinoma receiving tremelimumab with durvalumab.

LAMPGEN ANALYSIS

Why it matters

This introduces a CTLA-4 and PD-L1 combination for unresectable liver cancer.

What research teams should watch

Distinguish baseline liver disease from possible immune-mediated hepatic toxicity and track the two agents separately.

PRIMARY RECORDS

Sources